Evaluation of Trabecular Micro-Bypass Stent in Pseudophakia

Saturday, April 26, 2014: 3:11 PM
Room 154 (Boston Convention and Exhibition Center)
Tanner J. Ferguson, Morningside College, Dakota Dunes, SD, USA
Justin A. Schweitzer, OD, Vance Thompson Vision, Sioux Falls, SD, USA
John P. Berdahl, MD, Vance Thompson Vision, Sioux Falls, SD, USA

Narrative Responses:

Purpose
To evaluate safety and efficacy of the iStent Trabecular Micro-Bypass stent in pseudophakic patients with glaucoma.

Methods
A retrospective review was conducted of 25 consecutive eyes (n) with open-angle glaucoma or pseudoexfoliative glaucoma who received one iStent.  Data was collected pre-operatively, and at post-operative day 1, week 1, month 1, month 3 and month 6.  Data included mean IOP, number of glaucoma medications, visual acuity, and incidence of post-operative pressure increase greater than 15mmHg at any time point, and need for additional surgery.

Results
Mean pre-operative IOP was 22.2 +/- 8.4 mmHg.  Mean IOP at 6months was 17.6 +/- 5.9mmHg (p<0.01)  Mean pre-operative medication use was 1.5 +/-0.79 medications and at post-operative month 6 was 1.0 +/-0.87 medications (p=0.8). Mean pre-operative best spectacle corrected acuity was 0.3 +/-0.1 and at 6 months visual acuity was 0.18 +/- 0.1(p<0.05).  One eye had IOP increase ≥ 15 mmHg on post-operative week one that responded to topical therapy.

Conclusion
The iStent Trabecular Micro-Bypass stent is effective at lowering IOP in pseudophakic patients with glaucoma.  The safety profile through six months appears favorable with no need for additional surgeries.  Significant IOP reduction and medication reduction (though not significant) was shown in this series.